Appointment of Joint Broker

RNS Number : 2885Y

Shield Therapeutics PLC

08 May 2019

 

Shield Therapeutics plc

("Shield" or the "Group")

Appointment of Joint Broker

London, UK, 8 May 2019:  Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces the appointment of finnCap Ltd as its joint broker with immediate effect.

- Ends -

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Carl Sterritt, Chief Executive Officer	[phone]
Tim Watts, Chief Financial Officer
Nominated Advisor and Joint Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden	[phone]
Joint Broker
finnCap Ltd	[phone]
Geoff Nash /Matt Radley/ Alice Lane
Financial PR & IR Advisor
Walbrook PR	[phone] or [e-mail]
Paul McManus / Helen Cresswell	[phone] / [phone]

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.  Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27^th July 2019.  For more information please visit www.shieldtherapeutics.com. 

 

END

 

 

APPBRGDUDDGBGCR